Meru Networks, Inc (NASDAQ:MERU) shares closed at $3.86, Athersys, Inc (NASDAQ:ATHX)

Posted by Nathan Alexander June 4, 2013 0 Comment 1284 views


Meru Networks, Inc (NASDAQ:MERU): In Monday’s trading session, shares of Meru Networks, Inc (NASDAQ:MERU) dipped by 5.85%. The opening price of the shares was $4.07 which reached an intraday high of $4.11 before dropping to $3.86 per share. In excess of 0.2223M shares exchanged hands in the trading session on Monday. This number was lower than the average volume of 0.350M that was measured over 30-day period.

Meru Networks, Inc (NASDAQ:MERU) is a provider of a virtualized wireless local area network or LAN solution. Meru Networks, Inc (NASDAQ:MERU) enables enterprises to migrate applications that they have from wired networks to wireless networks. This is what the company refers to as an All-Wireless Enterprise. The company’s solution represents a relatively innovative approach to wireless networking. It is innovative in that it utilizes virtualization technology in the creation of a wireless network. Meru Networks, Inc (NASDAQ:MERU)’s solution is designed in such as way that it provides users with clear access to their various applications. The virtualized wireless LAN solution that is provided by the company is built around its System Director Operating System.

Athersys, Inc (NASDAQ:ATHX): In Monday’s trading session, shares of Athersys, Inc (NASDAQ:ATHX) dipped by 7.47%. The opening price of the shares was $1.71 which reached an intraday high of $1.78 before dropping to $1.61 per share. In excess of 0.966M shares exchanged hands in the trading session on Monday. This number was higher than the average volume of 0.676M that was measured over 30-day period.

Athersys, Inc (NASDAQ:ATHX ) is a based in the United States. The company is engaged in the development of therapeutic products. These products are used to treat different kinds of life-threatening as well as other diseases. Athersys, Inc (NASDAQ:ATHX ) produces therapeutic proteins, it validates biological-targets for development and it also conducts screening that is used in gene discovery. Currently, the company has different, active-therapeutic product development programs.

These programs are in the fields of oncology, neurobiology and inflammation. They include monoclonal antibody programs and small-molecule development programs. ATHX has initiated various development programs utilizing its proprietary adult stem-cell technology. This is in areas such as developmental disorders, tissue regeneration, neurobiology and immunology, amongst others.


About Nathan Alexander

Nathan Alexander holds bachelor’s degrees in Journalism and European Studies from Boston University. Nathan reports round up the day’s business and financial market news and include keynote interviews with major business players and updates on Asian, European and US stock markets. He has interviewed heads of leading European banking institutions such as European Central Bank President Jean-Claude Trichet and HSBC Chairman Stephen Green, and CEOs from the business world including Microsoft founder Bill Gates, Virgin Chairman Sir Richard Branson and former Porsche President and CEO Dr Wendelin Wiedeking.

View all post by Nathan Alexander Visit author's website

Write Your Comment